aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Septerna, founded with the mission to revolutionize GPCR drug discovery, focuses on creating novel small molecule medicines to address unmet medical needs. Utilizing their proprietary Native Complex Platform™, Septerna aims to unlock the therapeutic potential of G protein-coupled receptors (GPCRs), which play a crucial role in regulating various physiological processes. The company targets a broad market within the biotechnology and pharmaceutical sectors, striving to bring innovative treatments to patients.
Notable figures associated with Septerna include leading scientists and industry veterans who bring extensive expertise in drug discovery and development. The company has garnered significant attention and investment from prominent venture capital firms, underscoring its potential impact. Key achievements include advancing their platform technology and progressing multiple drug candidates through early development stages. Septerna's work promises to significantly impact future medical treatments by harnessing the power of GPCRs.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Small Molecule Drugs
Technology
Biotech
Tags
SaaS
Model Types
Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Septerna founded?
Septerna was founded in 2022.
Where is Septerna's headquarters located?
Septerna's headquarters is located in San Francisco, CA, US.
When was Septerna's last funding round?
Septerna's most recent funding round was for $150M (USD) in July 2023.
How many employees does Septerna have?
Septerna has 50 employees as of Feb 5, 2024.
How much has Septerna raised to-date?
As of July 05, 2023, Septerna has raised a total of $250M (USD) since Jul 11, 2023.
Add Comparison
Total Raised to Date
$250M
USD
Last Update Jul 11, 2023
Last Deal Details
$150M
USD
Jul 11, 2023
Series B
Total Employees Over Time
50
As of Feb 2024
Septerna Address
250 East Grand Avenue
Suite 65
San Francisco,
California
94080
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts